Compare · GELS vs NVO
GELS vs NVO
Side-by-side comparison of Gelteq Limited (GELS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GELS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.28B, about 11977.2x GELS ($16.4M).
- Over the past year, GELS is down 60.6% and NVO is down 45.9% - NVO leads by 14.7 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for GELS).
- NVO has more recent analyst coverage (25 ratings vs 0 for GELS).
- Company
- Gelteq Limited
- Novo Nordisk A/S
- Price
- $0.99-35.50%
- $43.88-0.20%
- Market cap
- $16.4M
- $196.28B
- 1M return
- +130.13%
- -6.80%
- 1Y return
- -60.56%
- -45.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 4
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GELS
- Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications
- Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion
- SEC Form 6-K filed by Gelteq Limited
- SEC Form 6-K filed by Gelteq Limited
- Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA
- Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth
- Healthy Extracts Reports 2025 Net Revenue Up 45% to Record $4.5 Million
- Healthy Extracts Reports Preliminary 2025 Results, Net Revenue Expected Up 45% to Record $4.5 Million
- SEC Form 6-K filed by Gelteq Limited
- SEC Form 3 filed by new insider Wynne Paul Michael
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care